Research programme: dual antimuscarinic/beta-2 adrenoceptor agonists - Pfizer
Alternative Names: PF-3429281Latest Information Update: 16 Jul 2016
At a glance
- Originator Pfizer
- Class
- Mechanism of Action Beta 2 adrenergic receptor agonists; Muscarinic receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Asthma; Chronic obstructive pulmonary disease
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Asthma in United Kingdom (Inhalation)
- 16 Jul 2016 No recent reports of development identified for preclinical development in Chronic-obstructive-pulmonary-disease in United Kingdom (Inhalation)